Recent results of the searches for Supersymmetry in final states with one or two leptons at CMS are presented. Many Supersymmetry scenarios, including the Constrained Minimal Supersymmetric extension of the Standard Model (CMSSM), predict a substantial amount of events containing leptons, while the largest fraction of Standard Model background events -which are QCD interactions -gets strongly reduced by requiring isolated leptons. The analyzed data was taken in 2011 and corresponds to an integrated luminosity of approximately L = 1 fb −1 . The center-of-mass energy of the pp collisions was √ s = 7 TeV.

A high mortality rate of approximately 20% in pregnant women with hepatitis E has been reported in previous studies. However, other studies showed no difference between pregnant and nonpregnant women in the severity of hepatitis E. To determine the effects of HEV infection on pregnancy, we successfully established HEV infection in six pregnant rabbits (PR) and six nonpregnant rabbits (NPR) with a rabbit HEV isolate, taking three PR and one NPR without HEV infection as controls. Tests for HEV RNA by RT-PCR, anti-HEV antibodies by ELISA and HEV antigen via immunohistochemistry and histopathology were carried out. Two of six infected PR miscarried and three of the remaining four PR died which may be attributed to severe liver necrosis caused by HEV infection. Moreover, vertical transmission was found to be associated with the replication of HEV in placenta, indicated by the presence of HEV RNA and antigen in placenta from the infected PR. Our findings strongly suggest that HEV infection could lead to adverse outcomes in pregnancy and vertical transmission, suggesting the necessity for pregnant women at risk of HEV infection to be vaccinated.

Developing energy-efficient parallel information processing systems beyond von Neumann architecture is a long-standing goal of modern information technologies. The widely used von Neumann computer architecture separates memory and computing units, which leads to energy-hungry data movement when computers work. In order to meet the need of efficient information processing for the data-driven applications such as big data and Internet of Things, an energy-efficient processing architecture beyond von Neumann is critical for the information society. Here we show a non-von Neumann architecture built of resistive switching (RS) devices named “iMemComp”, where memory and logic are unified with single-type devices. Leveraging nonvolatile nature and structural parallelism of crossbar RS arrays, we have equipped “iMemComp” with capabilities of computing in parallel and learning user-defined logic functions for large-scale information processing tasks. Such architecture eliminates the energy-hungry data movement in von Neumann computers. Compared with contemporary silicon technology, adder circuits based on “iMemComp” can improve the speed by 76.8% and the power dissipation by 60.3%, together with a 700 times aggressive reduction in the circuit area.

SUMMARYWhat is known and objective: To perform a meta-analysis exploring the optimal single-dose regimen for managing tumour lysis syndrome (TLS) in children and adults with haematological malignancies. Methods: We systematically searched PubMed, MEDLINE, Web of Science, the Cochrane Library and the ClinicalTrials.gov website for studies regarding single-dose rasburicase in paediatric and adult patients with TLS. Data were analysed using Open MetaAnalyst statistical software. Results: Fifteen adult studies (fourteen retrospective studies and one randomized controlled trial) and four observational studies using children were extracted, with a total of 906 and 92 subjects, respectively. Single doses of 1Á5, 3, 4Á5, 6, 7Á5 mg and weight-based single doses of 0Á05 and 0Á15 mg/kg were compared. The response rate for 6, 7Á5 mg and 0Á15 mg/kg single doses was 90% (95% CI: 0Á825-0Á974), 98Á6% (95% CI: 0Á957-1Á015) and 93Á6% (95% CI: 0Á864-1Á007), respectively, and higher than other dosing regimens tested. The single doses of 6 mg and 0Á15 mg/kg rasburicase decreased uric acid levels more than the other regimens, and the mean uric acid reduction was 8Á45 mg/dL (95% CI, 7Á51-9Á38) and 10 mg/dL (95% CI, 8Á58-11Á42), respectively. What is new and conclusion: Our meta-analysis revealed that, for adult patients, a single 6 mg rasburicase dose is sufficient to normalize and sustain lower uric acid and creatinine levels in adults with TLS. This dose, therefore, balances cost and efficacy of treatment. The 3-and 4Á5-mg single dose can be considered if the baseline uric acid level <12 mg/dL, with close monitoring of clinical and biochemical parameters, and repeat dosing if required. The 1Á5 mg and 0Á15 mg/kg single dose were sufficient to manage TLS in children. WHAT IS KNOWN AND OBJECTIVETumour lysis syndrome (TLS) is a frequently encountered and lifethreatening oncologic emergency. It is characterized by severe electrolyte and metabolite abnormalities caused by rapid and massive breakdown of cancer cells and release of intracellular content into the systemic circulation, which leads to severe complications, such as hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcaemia.1,2 TLS occurs most commonly within 12-72 h after initiation of cytoreductive chemotherapy of haematological malignancies, especially in non-Hodgkin lymphoma and acute lymphocytic leukaemia (ALL), as well as in solid tumours that are characterized by high sensitivity to cytotoxic treatment, high proliferative rate or large tumour size or burden; however, it can also occur spontaneously without chemotherapy. 2-4Numerous studies have demonstrated that rasburicase is effective and safe in reducing uric acid (UA) levels and works within 4 h post-administration. [5][6][7][8] Rasburicase was approved by the US FDA for the treatment and prophylaxis of hyperuricemia in paediatric and adult patients with leukaemia, lymphoma or solid tumours who are receiving chemotherapy or at high risk of TLS, in 2002 and 2009, respectively. The recommended dose by the FDA i...